A phase 2 study of tandutinib in patients with newly diagnosed acute myelogenous leukemia who are considered ineligible for or who decline treatment with standard induction therapy
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 05 Nov 2013
At a glance
- Drugs Tandutinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 04 Jun 2008 Status changed from in progress to withdrawn prior to recruitment.
- 08 Aug 2006 New trial record.